Related Experiment Video

Updated: Nov 9, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.3K

Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!

Arushi Khurana1, Matthew J Maurer2

  • 1Division of Hematology, Mayo Clinic, Rochester, MN, USA.

British Journal of Haematology
|April 14, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.0K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K

Related Experiment Videos

Last Updated: Nov 9, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.3K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.0K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

A framework to challenge the dogma of incurability in follicular lymphoma.

Blood·2026

Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas.

Research square·2026

Risk of Bias Associated with Varying Sampling Strategies for External Comparator Cohorts for Single-Arm Trials: Insights from Aggressive Lymphoma.

Clinical pharmacology and therapeutics·2026

No Association of Prior Administration of Selected Vaccines with Lymphoma Prognosis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal·2026

Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents.

British journal of haematology·2026

BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection.

British journal of haematology·2026

Development and validation of a machine learning model based on routine laboratory tests for predicting FLT3-ITD mutations in acute myeloid leukaemia.

British journal of haematology·2026

Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV, open-label, single-centre trial.

British journal of haematology·2026

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.

British journal of haematology·2026

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us